ClinicalTrials.gg
RecruitingNCT06287034Updated Jun 5, 2026

The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF)

An observational study in Larynx Carcinoma, sponsored by Regina Elena Cancer Institute. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Regina Elena Cancer Institute · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter, prospective, randomized study aimed at evaluating the difference in risk of PCF after salvage laryngectomy in two groups of patients: one cohort treated with Total Laryngectomy (LT) with primary suture, a second group treated with LT and reinforcement by flap positioning with onlay technique (PMM, ALT)

Read the detailed description

Patients, once eligibility has been verified, will then be randomized (1:1) to one of the following groups: Gruop 1: STL primary suture. Group 2: STL primary suture + onlay flap Patients in both groups will then undergo surgery STL with primary suture; in those of the second group, in addition, the positioning of a free/pedunculated covering flap will also be carried out with the onlay technique. 4 months after surgery, questionnaires will be administered to the patient for the subjective evaluation of the quality of life in relation to vocal rehabilitation obtained through voice prosthesis or esophageal voice (SECEL questionnaire) and swallowing rehabilitation (SOAL questionnaire). Demographic and preoperative data will be collected, data relating to pre-(chemo-)radiotherapy and pre-STL clinical staging, as well as the interval in days between the end of (chemo-)radiotherapy and surgery, perioperative data, type of eventual unilateral or bilateral laterocervical lymph node emptying, the type of pharyngotomy suture, the type of flap possibly used, the packaging of the tracheoesophageal fistula for positioning the voice prosthesis, the definitive histological examination.

The patient must undergo a radiological examination for loco-regional and distant staging before the STL (CT or MRI) and a biopsy demonstrating the recurrence/persistence of the disease.

02

Conditions studied

  • Larynx Carcinoma

Browse trials for

Keywords

  • pharyngocutaneous fistula
03

In context

Laryngeal Neoplasms

258 studies on the registry are indexed under Laryngeal Neoplasms; 69 are open to participants now.

This study's planned enrollment of 102 is close to the median of 100 across 61 observational studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

Regina Elena Cancer Institute is the lead sponsor of 95 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients suffering from recurrence/persistence of laryngeal SCC following exclusive RT treatment or concomitant RT/ChT without extension to the pharynx (rcT1/T2/T3 selected rcT4a N0/N+) who will have to undergo STL and who will meet the following criteria. Patients undergoing extensive laryngectomies or with disease with even partial involvement of the pharyngeal mucosa (pyriform sinus, posterior wall of the pharynx) will not be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of recurrence/persistence of squamous cell carcinoma of the larynx previously subjected to exclusive radiotherapy or concomitant chemo-radiotherapy treatment:

    1. pre (ChT-)RT staging: cT1/T2/T3 N0/N+;
    2. pre STL staging: rcT1/cT2/ Selected cT3 cT4a (extension to thyroid cartilage and/or prelaryngeal tissues) N0/N+ (clinically and radiologically).
  • Indication for STL surgery (no pharyngeal mucosal resection);
  • Functional total laryngectomies after radical (chemo-)radiotherapy treatment;
  • Age > 18 years;
  • Signature of and ability to complete in-office questionnaires.

Exclusion criteria

Exclusion Criteria:

  • STL extended to the pharynx and/or total pharyngeal laryngectomies;
  • Extension of the tumor to the pharyngeal mucosa and/or massive extra-laryngeal extension;
  • Previous open organ preservation surgery (OPHL).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No

Groups and cohorts

  • Salvage total laryngectomy STL primary suture

    Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing.The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)31. It would be preferable for all centers to use a homogeneous pharyngeal suture technique, such as the T-shaped with Connell suture.

    Procedure: Primary suture

  • Salvage total laryngectomy STL primary suture + onlay flap

    Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing, but in the patients of the second group, in addition, the positioning of a free/pedunculated covering flap will also be carried out with the onlay technique. Reconstruction with the onlay technique can be performed using a pedicled pectoralis major myofascial flap or anterolateral thigh myofascial free flap at the surgeon's discretion (pharyngeal suture unchanged). The flap will be positioned with an onlay technique to reinforce the pharyngeal suture and in turn sutured to the prevertebral fascia or residual surrounding tissues.

    Procedure: Primary suture

Interventions

  • ProcedurePrimary suture

    The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)

06

What researchers measure

Primary outcomes

  1. questionnaires for evaluation of the quality of life

    Questionnaires will be administered to the patient for the subjective evaluation of the quality of life in relation to vocal rehabilitation obtained through voice prosthesis or esophageal voice (SECEL questionnaire).

    Time frame: 30 months

Secondary outcomes

  1. Identification of risk factors

    Identification of risk factors related to the formation of pharyngocutaneous fistulas after salvage total laryngectomy

    Time frame: 4 months

  2. Evaluation of swallowing function

    Evaluation of swallowing function assessed using the SOAL questionnaire

    Time frame: 4 months

  3. Evaluation of vocal rehabilitation

    Evaluation of vocal rehabilitation using the SECEL questionnaire

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2025, 24 months.

Of 27 observational studies under Laryngeal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 172. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Feb 29, 2024
StartActual
Mar 21, 2023
Primary completionActual
Mar 21, 2025
CompletionEst.
Sep 21, 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06287034
Lead sponsor
Regina Elena Cancer Institute
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 21, 2023
Primary completion
Mar 21, 2025
Completion
Sep 21, 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Raul Pellini, Doctor
Contact
raul.pellini@ifo.it
06-52664484 ext. +39
Raul Pellini, Doctor
principal investigator · IRCCS "Regina Elena" National Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion